These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 8631017

  • 21. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T, Nakajima Y, Mizobuchi M, Inazawa K, Kanazu T, Kadono K, Ohkawa T, Iwatani K.
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
    Sugimoto T, Hayashi T, Okita A, Morino A.
    Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
    [Abstract] [Full Text] [Related]

  • 23. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
    Hornung RL, Pearson JW, Beckwith M, Longo DL.
    Cancer Res; 1992 Jan 01; 52(1):101-7. PubMed ID: 1727368
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
    Zhang R, Iyer RP, Yu D, Tan W, Zhang X, Lu Z, Zhao H, Agrawal S.
    J Pharmacol Exp Ther; 1996 Aug 01; 278(2):971-9. PubMed ID: 8768755
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration.
    Giri SN, Wang Q, Xie Y, Lango J, Morin D, Margolin SB, Buckpitt AR.
    Biopharm Drug Dispos; 2002 Jul 01; 23(5):203-11. PubMed ID: 12116052
    [Abstract] [Full Text] [Related]

  • 27. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, Melillo D, Doss G, Vyas KP.
    Drug Metab Dispos; 2000 Oct 01; 28(10):1244-54. PubMed ID: 10997947
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.
    Mountfield RJ, Kiehr B, John BA.
    Drug Metab Dispos; 2000 May 01; 28(5):503-13. PubMed ID: 10772628
    [Abstract] [Full Text] [Related]

  • 33. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y, Hua Y, Benbrook DM, Covey JM, Dai G, Liu Z, Chan KK.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):561-9. PubMed ID: 16534614
    [Abstract] [Full Text] [Related]

  • 34. Distribution, elimination, and test for carcinogenicity of 2,6-dinitrotoluene after intraperitoneal and oral administration to strain a mice.
    Schut HA, Loeb TR, Grimes LA, Stoner GD.
    J Toxicol Environ Health; 1983 Nov 01; 12(4-6):659-70. PubMed ID: 6668616
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of guanosine in rats following intravenous or intramuscular administration of a 1:1 mixture of guanosine and acriflavine, a potential antitumor agent.
    Shin DH, Choi KS, Cho BS, Song S, Moon DC, Hong JT, Lee CK, Chung YB.
    Arch Pharm Res; 2008 Oct 01; 31(10):1347-53. PubMed ID: 18958427
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL.
    Cancer Chemother Pharmacol; 2001 Apr 01; 47(4):291-302. PubMed ID: 11345645
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
    Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH.
    Clin Cancer Res; 1997 Nov 01; 3(11):2047-53. PubMed ID: 9815596
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.